Toxicity Management Across Treatment Lines for GIST

Dr. Schulte outlines toxicity management strategies across the GIST treatment sequence, emphasizing proactive patient education and monitoring. Imatinib's 25-year track record provides community comfort with characteristic side effects including edema, myalgias, and gastrointestinal irritation, managed with full stomach dosing and symptomatic measures.

Sunitinib introduces more complex toxicity management requiring blood pressure monitoring, cardiac function assessment, and potential organ damage surveillance. The broader array of laboratory monitoring and longitudinal complications like osteonecrosis of the jaw necessitates multidisciplinary coordination.

Regorafenib's distinct dosing schedule (3-weeks-on/1-week-off) provides built-in recovery periods while requiring hepatotoxicity monitoring reflected in black box warnings. Hand-foot skin reaction management and dose modification strategies become crucial for maintaining treatment intensity.

Ripretinib presents unique toxicity patterns including severe but self-limited myalgia during the first week that resolves and rarely recurs unless treatment is interrupted for extended periods. This requires patient counseling and short-term analgesic support to prevent premature discontinuation.

Dr. Heinrich emphasizes creative dosing strategies to optimize tolerability while maintaining efficacy, such as taking regorafenib for 17 days with 11-day breaks if standard scheduling proves intolerable. The principle involves finding individualized doses patients can tolerate long-term rather than rigidly adhering to label dosing when modifications preserve disease control.